Compare Adaptive Biotechnologies Corp (ADPT) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Yum! Brands, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Yum! Brands, Inc. trades at $167.25 (market cap $46.16B). The key difference: Yum! Brands, Inc. is far larger — about 13.9× Adaptive Biotechnologies Corp's market cap, and Yum! Brands, Inc. pays a 1.79% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | YUM | |
|---|---|---|
Market Cap | $3.33B | $46.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $168.16 |
52-Week Low | $10.24 | $138.21 |
Enterprise Value | $3.19B | $57.43B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
YUM trades at $167.49, up 1.68% today, near its consensus price target of $174.00. The stock shows a bullish technical trend with strong moving averages, though RSI indicates potential overbought conditions. Fundamentals are solid with revenue growth from $7.5B in 2024 to $8.2B in 2025 and a net income margin of 20.48%. Recent news highlights the $2.7 billion sale of Pizza Hut, aimed at streamlining operations and funding a $4 billion share repurchase, signaling strategic focus on KFC and Taco Bell.
The outlook for YUM is cautiously optimistic, supported by earnings beats and strategic divestiture, but high debt levels and competitive pressures pose risks. Analyst consensus leans hold with a 37.25% buy rating, suggesting moderate upside potential. Investors should weigh the benefits of capital returns against execution risks in a challenging consumer discretionary environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
